Languages Available
 
C

PT. Indofarma (Persero) Tbk [INAF]   IDR 4.550  -70 (-1,52%)


Loading...
INAF IDR 4.550  -70 (-1,52%)
Last Update 20 February 2018 04:00 PM
Open
IDR 4.600
Prev Close
IDR 4.620
Offer
IDR 4.560
Bid
IDR 4.550
Day Low
IDR 4.530
Day High
IDR 4.640
Volume
304 Lots (30.400 Shares)
Value (IDR)
139,60 M
Frequency
76 (Times)
EPS (IDR)
-34,55
PE Ratio (ttm)
-131,69 Times
Market Cap. (IDR)
14.100.450,00 M
Market Cap. Rank in Industry
#2 of 10 Companies in Pharmaceuticals
Market Cap. Rank in All Companies
#79 of 589 Companies
F
Net Foreign

This section of IDNFinancials requires you to sign up as a premium member of IDNFinancials.

Please check our pricing page to see all of our features.
O
Overview


PT. Indofarma (Persero) Tbk (INAF) is a manufacturer of drug, which consists of several product categories, namely Unbranded Generic or OTC Over the Counter (OTC), branded generic, rapid diagnostic test, and others. In addition, it also produces packaging materials, machinery, equipment and infrastructure related to pharmaceutical and other industries. The company commenced its commercial operations and production on 1983. The company’s products are marketed both domestically and internationally.

Subsidiary Affiliation
 
Company Name
Percentage
1.
PT. Indofarma Global Medika
99,99 %
G
Management
Commissioners
-
President Commissioner
Commissioner
Independent Commissioner
Teddy Wibisana
Directors
-
President Director
Rusdi Rosman
Director
Director
Wahyuli Syafari
Graph goes here...
S
Shareholders
No. Shareholder Name Number of Shares Total Paidup Capital Percentage
1. (Serie B) - Goverment of The Republic of Indonesia 2.499.999.999 IDR 249.999.999.900 80,66 %
2. (Serie B) - Public (each below 5%) 399.271.000 IDR 39.927.100.000 12,88 %
3. (Serie B) - PT. ASABRI (Persero) 199.996.500 IDR 19.999.650.000 6,45 %
4. (Serie A) - Goverment of The Republic of Indonesia (Dwiwarna) 1 IDR 100 3e-10 %
V
Videos
IDNFinancials Video - Company profile PT Indofarma Tbk
10 January 2013 09:02 AM
Company profile PT Indofarma Tbk
S
News Update
10 August 2015 11:04 AM Indofarma Targets 15-20% Margin Growth yosefardi.biz
09 September 2015 04:43 PM Siti Fadilah testifies medical equipments case trial yosefardi.biz
A
Announcement
Suspension of Indofarma's stock trading has been lifted from December 27, 2017
2017-12-22 23:00:33
Links: [1] [2]
Indofarma's stock have been suspended from trading since December 22, 2017
2017-12-21 18:19:22
Links: [1] [2]
Indofarma (Persero) will hold annual shareholders' meeting on April 20, 2017
2017-03-10 11:00:02
Links: [1]
Indofarma will hold annual shareholders' meeting on April 6, 2016
2016-02-22 23:05:27
Links: [1] [2]
S
Financial
Period Revenue Net Profit
Q3 - 2017 295.125 M -10.608 M
Q2 - 2017 273.309 M -18.708 M
Q1 - 2017 207.912 M -34.831 M
Q4 - 2016 806.075 M 13.041 M
Q3 - 2016 397.308 M -2.542 M
Q2 - 2016 269.820 M -8.291 M
Q1 - 2016 201.499 M -19.574 M
Q4 - 2015 826.476 M 38.539 M
Full financial and operational data available to our premium users. Please check our premium data introduction page to learn more about our tools.
No prospectus found